J&J Says This Lung Cancer Combo Delivers Nearly 3 Years of Survival. There's a Catch.
J&J's amivantamab combo just posted the longest survival ever in a rare lung cancer subtype: 34.3 months. But the key statistical test came back negative, and a rival oral drug is gaining ground fast. The full story is more nuanced than the headline.
A Record That Comes With an Asterisk
Nearly three years. That's how long patients with a rare, hard-to-treat form of lung cancer lived, on average, when treated with Johnson & Johnson's amivantamab (brand name Rybrevant) plus chemotherapy. It's the longest median overall survival ever reported for this specific cancer subtype. And J&J is, understandably, shouting it from the rooftops.
But buried in the data is a statistical detail that makes this story a lot more complicated than the press release suggests. The survival difference wasn't statistically significant. Which means, by the cold standards of clinical trial math, the result could have happened by chance.
So which is it: a genuine breakthrough or an impressive number that doesn't hold up to scrutiny? The answer, frustratingly, is somewhere in between.
The Trial That Set the Bar
Let's rewind. The PAPILLON trial tested amivantamab plus standard chemo (carboplatin and pemetrexed) against chemo alone in patients with advanced non-small cell lung cancer (NSCLC) driven by a specific genetic glitch called an EGFR exon 20 insertion mutation.
Think of EGFR mutations as typos in a gene that tells cells to grow. Most EGFR typos in lung cancer respond beautifully to targeted pills. But the exon 20 insertion variety? It's the stubborn cousin that shrugs off most of those drugs. For years, the best option was plain old chemotherapy, which is a bit like using a sledgehammer when you really want a scalpel.
Amivantamab changed that. It's a bispecific antibody, meaning it grabs onto two targets at once (EGFR and MET) on the surface of cancer cells, blocking their growth signals and flagging them for destruction by the immune system. Back in 2023, the PAPILLON trial showed that adding amivantamab to chemo nearly doubled progression-free survival: 11.4 months versus 6.7 months, with a hazard ratio of 0.40. That's a dramatic result, and it made amivantamab plus chemo the new standard of care.
Now we have the final overall survival data, reported with a median follow-up of (roughly four years of tracking patients).
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
48.6 months
The Numbers: Impressive and Inconclusive
Patients who got amivantamab plus chemo lived a median of 34.3 months. Those on chemo alone lived 27.9 months. That's a 6.4-month advantage, and investigator Chul Kim called it the "longest reported median overall survival to date" in this patient population.
Sounds great, right? But the hazard ratio was 0.87, with a p-value of 0.307. In clinical trial language, that means the difference didn't cross the threshold for statistical significance. If this were a court case, the jury would say "not proven."
So how can J&J claim a record while the statistics say "meh"? The answer involves one of the trickiest problems in cancer research.
The Crossover Problem (a.k.a. Why This Trial Was Fighting Itself)
Imagine you're running a taste test between two sodas. Halfway through, 42% of the people drinking Soda B switch to Soda A. At the end, both groups rate their experience similarly. Does that mean Soda A isn't better? Or does it mean the test was contaminated by all the switching?
That's essentially what happened in PAPILLON. A substantial 42% of eligible patients in the chemo-only arm crossed over to receive amivantamab after their cancer progressed. This is ethically appropriate (you don't deny patients a promising drug), but it makes the final survival comparison muddy. If a large portion of the control group eventually gets the experimental treatment, the two groups start to look alike.
To account for this, the trial used a statistical method called IPCW (inverse probability of censoring weighting), which tries to estimate what would have happened without crossover. That adjusted analysis told a very different story: the hazard ratio shrank to a much more impressive 0.57, with a nominal p-value of 0.003.
In other words, once you correct for the fact that many control patients eventually got amivantamab too, the survival benefit looks substantial.
The "Yeah, But" Section
Crossover-adjusted analyses are useful, but they're not the gold standard. They involve assumptions and modeling, which is why the FDA and most statisticians put more weight on the unadjusted, intention-to-treat result. And that result was not significant.
There's also the inconvenient truth that amivantamab is an IV infusion, not a pill. It comes with a side effect profile that includes rash, nail toxicity, infusion reactions, and low blood counts (on top of chemo's own side effects). In the original PAPILLON analysis, about 7% of patients discontinued amivantamab because of treatment-related adverse events.
For a rare cancer subtype where options have historically been terrible, these trade-offs are worth it. But a competitor is lurking that could change the calculus.
Zipalertinib: The Oral Challenger at the Gates
While J&J was celebrating PAPILLON's survival data, a small-molecule pill called zipalertinib has been quietly building its own case. In the REZILIENT1 study, zipalertinib showed a confirmed response rate of 35.2% in pretreated patients, including a 30% response rate in patients who had already failed amivantamab. That's notable; it means zipalertinib works even after J&J's drug stops working.
More importantly, the phase 3 REZILIENT3 trial (zipalertinib plus chemo in the first-line setting) met its primary PFS endpoint at an interim analysis in 2026. No head-to-head data exist comparing the two drugs directly, so we can't say one is definitively better. But zipalertinib has a major practical advantage: patients can take it at home as a pill instead of sitting in an infusion chair.
If REZILIENT3's survival data eventually rival PAPILLON's, J&J's reign as the standard-setter in this space could face a serious challenge.
What This Means for Patients (and Investors)
For patients with EGFR exon 20 insertion NSCLC right now, amivantamab plus chemo remains the clear first-line standard of care. A median survival approaching three years is genuinely remarkable for a subtype that used to be a therapeutic dead end. The crossover-adjusted data strongly suggest the drug is doing real, meaningful work.
For J&J, the story is more nuanced. The missed statistical significance gives competitors an opening to argue that the survival benefit isn't proven in the strictest sense. And with zipalertinib's oral convenience and a positive phase 3 PFS readout in hand, the competitive pressure is only going to intensify.
The bottom line: PAPILLON delivered the longest survival ever seen in this cancer. It just can't prove, beyond statistical doubt, that it deserves all the credit. In oncology, that kind of ambiguity is the norm rather than the exception. And for patients who had almost nothing a few years ago, 34.3 months isn't an asterisk. It's a lifeline.
Clinical & Regulatory
4 min read
Two Shots a Year. Two Infections Out of 2,180 People.
Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 people in the PURPOSE 2 trial, crushing daily Truvada by 89%. The science is settled; now comes the hard part.
